901 Gateway Boulevard
South San Francisco
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
137 articles with Theravance Biopharma
Theravance Biopharma Reports Encouraging Data From First Cohort Of Patients In Phase Ib Clinical Trial Of TD-1473 In Ulcerative Colitis
Theravance Biopharma Announces Positive Top-Line Results From Phase IIb Study Of Velusetrag (TD-5108) In Patients With Gastroparesis
Theravance Biopharma To Report Second Quarter 2017 Financial Results And Business Update On August 8, 2017
Theravance Biopharma Appoints Shehnaaz Suliman, MD, As Senior Vice President Of Corporate Development And Strategy
Theravance Biopharma AndMylan Announce Positive Results From 12-Month Phase III Safety Study Of Revefenacin (TD-4208) In Patients With Chronic Obstructive Pulmonary Disease (COPD)
Theravance Biopharma Release: New Data Highlighting In Vitro Potency Advantages For VIBATIV (Telavancin) Against Difficult-To-Treat MRSA And MSSA Pathogens Reported At ASM Microbe 2017
Theravance Biopharma And Mylan Report Additional Phase lll Data For Revefenacin (TD-4208) In Several Presentations At 2017 American Thoracic Society
Theravance Biopharma Release: New Data For VIBATIV (Telavancin) Reported In Several Presentations At ECCMID 2017
Theravance Biopharma Reports Positive Clinical Response Rates For Patients In TOUR Observational Patient Registry In Several Presentations At ECCMID 2017
Theravance Biopharma Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update
Theravance Biopharma Presents Positive Clinical Data On TD-1473 At The 12th Congress Of The European Crohn's And Colitis Organization
Theravance Biopharma To Report Fourth Quarter And Full Year 2016 Financial Results On February 27, 2017
Theravance Biopharma Release: Company Reports New Data From Ongoing TOUR Observational Patient Registry In Oral Presentation At SCCM Critical Care Congress
Theravance Biopharma Highlights Initiation Of Phase 3 Study Of The Closed Triple In Patients With Asthma By GlaxoSmithKline And Innoviva Inc.
Theravance Biopharma Receives FDA Fast Track Designation For Velusetrag (TD-5108) For Idiopathic And Diabetic Gastroparesis
Theravance Biopharma Highlights Filing Of EU Regulatory Submission For The Closed Triple In COPD By GlaxoSmithKline And Innoviva Inc.
Theravance Biopharma Highlights Filing Of U.S. New Drug Application For The Closed Triple In COPD By GlaxoSmithKline And Innoviva Inc.